Compare OGN & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | CET |
|---|---|---|
| Founded | 1923 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | N/A |
| Metric | OGN | CET |
|---|---|---|
| Price | $13.38 | $53.07 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.40 | N/A |
| AVG Volume (30 Days) | ★ 5.0M | 32.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | 0.60% | ★ 5.12% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | $0.45 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $24.28 | ★ $6.93 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $46.05 |
| 52 Week High | $13.48 | $54.28 |
| Indicator | OGN | CET |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 54.61 |
| Support Level | $10.05 | $50.76 |
| Resistance Level | $13.46 | $53.97 |
| Average True Range (ATR) | 0.05 | 0.73 |
| MACD | -0.22 | -0.06 |
| Stochastic Oscillator | 47.50 | 53.99 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Central Securities Corp is a non-diversified closed-end management investment company. The company's investment objective is long-term growth of capital. It invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.